INSM

Cantor Fitzgerald Reiterates Insmed (INSM) Overweight Recommendation

Fintel reports that on September 19, 2023, Cantor Fitzgerald reiterated coverage of Insmed (NASDAQ:INSM) with a Overweight recommendation.

Analyst Price Forecast Suggests 56.63% Upside

As of August 31, 2023, the average one-year price target for Insmed is 41.58. The forecasts range from a low of 30.30 to a high of $54.60. The average price target represents an increase of 56.63% from its latest reported closing price of 26.55.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Insmed is 338MM, an increase of 25.53%. The projected annual non-GAAP EPS is -4.04.

What is the Fund Sentiment?

There are 518 funds or institutions reporting positions in Insmed. This is a decrease of 19 owner(s) or 3.54% in the last quarter. Average portfolio weight of all funds dedicated to INSM is 0.21%, an increase of 18.76%. Total shares owned by institutions increased in the last three months by 0.29% to 167,254K shares. INSM / Insmed Inc Put/Call Ratios The put/call ratio of INSM is 3.10, indicating a bearish outlook.

What are Other Shareholders Doing?

INSM / Insmed Inc Shares Held by Institutions

Price T Rowe Associates holds 10,172K shares representing 7.07% ownership of the company. In it's prior filing, the firm reported owning 9,982K shares, representing an increase of 1.87%. The firm increased its portfolio allocation in INSM by 164.84% over the last quarter.

T. Rowe Price Investment Management holds 8,304K shares representing 5.77% ownership of the company. In it's prior filing, the firm reported owning 8,415K shares, representing a decrease of 1.34%. The firm increased its portfolio allocation in INSM by 16.02% over the last quarter.

Deep Track Capital holds 6,500K shares representing 4.52% ownership of the company. No change in the last quarter.

Palo Alto Investors holds 5,889K shares representing 4.10% ownership of the company. No change in the last quarter.

Macquarie Group holds 4,391K shares representing 3.05% ownership of the company. In it's prior filing, the firm reported owning 4,052K shares, representing an increase of 7.71%. The firm increased its portfolio allocation in INSM by 38.66% over the last quarter.

Insmed Background Information
(This description is provided by the company.)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. .

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.